- Home
- JAZZ vs OMF Comparison
JAZZ vs OMF Comparison
Compare JAZZ & OMF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- OMF
- Stock Information
- Founded
- JAZZ 2003
- OMF 1920
- Country
- JAZZ Ireland
- OMF United States
- Employees
- JAZZ N/A
- OMF N/A
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- OMF Finance: Consumer Services
- Sector
- JAZZ Health Care
- OMF Finance
- Exchange
- JAZZ Nasdaq
- OMF Nasdaq
- Market Cap
- JAZZ 7.1B
- OMF 6.7B
- IPO Year
- JAZZ 2007
- OMF 2013
- Fundamental
- Price
- JAZZ $124.15
- OMF $61.74
- Analyst Decision
- JAZZ Strong Buy
- OMF Buy
- Analyst Count
- JAZZ 12
- OMF 8
- Target Price
- JAZZ $182.75
- OMF $61.50
- AVG Volume (30 Days)
- JAZZ 879.8K
- OMF 856.9K
- Earning Date
- JAZZ 08-05-2025
- OMF 07-25-2025
- Dividend Yield
- JAZZ N/A
- OMF 6.75%
- EPS Growth
- JAZZ N/A
- OMF 14.13
- EPS
- JAZZ N/A
- OMF 5.55
- Revenue
- JAZZ $4,086,695,000.00
- OMF $2,759,000,000.00
- Revenue This Year
- JAZZ $5.65
- OMF $71.41
- Revenue Next Year
- JAZZ $5.79
- OMF $19.14
- P/E Ratio
- JAZZ N/A
- OMF $11.10
- Revenue Growth
- JAZZ 4.52
- OMF 9.79
- 52 Week Low
- JAZZ $95.49
- OMF $38.00
- 52 Week High
- JAZZ $148.06
- OMF $61.81
- Technical
- Relative Strength Index (RSI)
- JAZZ 66.76
- OMF 68.88
- Support Level
- JAZZ $122.50
- OMF $57.21
- Resistance Level
- JAZZ $126.14
- OMF $58.62
- Average True Range (ATR)
- JAZZ 2.50
- OMF 1.10
- MACD
- JAZZ 0.80
- OMF 0.45
- Stochastic Oscillator
- JAZZ 87.44
- OMF 98.75
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About OMF OneMain Holdings Inc.
OneMain Holdings Inc is a consumer finance company providing loan products to customers through its branch network and the internet. The company provides personal loan products; offers credit cards; offers optional credit insurance and others; offers a customer-focused financial wellness program, and acquisitions and dispositions of assets and businesses. It provides origination, underwriting, and servicing of personal loans to non-prime customers. The company's reportable segment is Consumer and Insurance. The main source of revenue is net interest income.